Abu Dhabi, United Arab Emirates: Biogenix Labs, a G42 Healthcare company, has announced that it is providing COVID-19 testing services for the newly launched IATA Travel Pass, a digital platform that passengers travelling with Etihad Airways, the national carrier of the United Arab Emirates, can use to seamlessly fly between Abu Dhabi and Chicago, New York, Washington and Toronto until 31st May 2021.
Launched at the beginning of April by the International Air Transport Association, the Travel Pass app offers simple and secure management of health-related requirements. The information on the Travel Pass can be shared with border authorities that require testing as a condition for international travel during and after the COVID-19 pandemic. By using the app, passengers will be able to easily manage their travel health credentials, take advantage of faster check-in facilities, and have access to free Wi-Fi while on board.
Given the scale of operations and quick turnaround requirements of the Travel Pass app program, Biogenix Labs was selected as a testing partner thanks to its high throughput processing, 24/7 operations and secure handling of sensitive data. Biogenix Labs already supports travelers’ testing needs in compliance with the constantly evolving regulatory guidelines and is thus well-positioned to contribute to the Travel Pass initiative through its flexibility, agility, and rapid response.
Its inclusion in the scheme is a testament to the company’s abilities and trustworthiness to support the efforts to re-introduce safe flying protocols and seamless travel.
Ashish Koshy, CEO of G42 Healthcare, said: “We are proud to be part of this pioneering project. Biogenix Labs is contributing to the lifting of travel restrictions using digital solutions and working with leaders in the travel industry to process verified information in a safe and secure manner. This collaboration is a testament to our lab’s capability and trustworthiness, and a major game-changer for the aviation industry, one that we hope will usher in a new phase of international air travel.”
Biogenix Labs was the first COVID-19 accredited laboratory in the UAE, supporting the population with their testing needs. It led the validation of non-invasive saliva testing resulting in approval and subsequent adoption by Department of Health, Abu Dhabi. The lab also pioneered the enablement of the safe return of sporting events, and has supported the 4Humanity vaccine trials across geographies, leading to national vaccination rollouts in multiple countries.
To take advantage of the IATA Travel Pass benefits, passengers can download the app from the Apple Store and book an appointment with Biogenix Labs in Masdar City, where guests should inform the staff that they are participating in the IATA Travel Pass trial, presenting their passport along with their mobile device with the app installed. As soon as the test result is available, travelers will be able to view it on the app as well as via an SMS from the lab, making it much more convenient for passengers to manage their travel documentation.
Biogenix Labs utilizes the latest technology to provide the most accurate results in the shortest timespan and also provides testing services for passengers who do not wish to participate in the app trial as they can continue to follow the existing method of sharing PCR test results by presenting a printed copy at the airport check in.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
